{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"332"}]}],"title":"Antiviral BL, Normal, n=232, 478"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"103"}]}],"title":"Antiviral BL, Abnormal - NCS, n=232, 478"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"43"}]}],"title":"Antiviral BL, Abnormal - CS, n=232, 478"},{"categories":[{"measurements":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"291"}]}],"title":"End of Treatment, Normal, n=218, 428"},{"categories":[{"measurements":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"103"}]}],"title":"End of Treatment, Abnormal - NCS, n=218, 428"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"34"}]}],"title":"End of Treatment, Abnormal - CS, n=218, 428"},{"categories":[{"measurements":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"238"}]}],"title":"24-week FU, Normal, n=194, 383"},{"categories":[{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"107"}]}],"title":"24-week FU, Abnormal - NCS, n=194, 383"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"38"}]}],"title":"24-week FU, Abnormal - CS, n=194, 383"},{"categories":[{"measurements":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"233"}]}],"title":"Worst ECG post-BL, Normal, n=252, 505"},{"categories":[{"measurements":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"171"}]}],"title":"Worst ECG post-BL, Abnormal - NCS, n=252, 505"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"101"}]}],"title":"Worst ECG post-BL, Abnormal - CS, n=252, 505"}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"505"}],"units":"Participants"}],"description":"Duplicate 12-lead ECGs were required at Screening/BL, Antiviral BL, and at 12 weekly intervals during the study. The number of participants with an ECG status of normal, abnormal, CS, or NCS, as determined by the Investigator, was reported. Normal, all ECG parameters within accepted normal ranges. Abnormal, ECG finding(s) outside of normal ranges. CS, ECG with a CS abnormality that meets exclusion criteria. NCS, ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment.","groups":[{"description":"Participants completing the OL Phase were administered matching placebo tablets QD in combination with antiviral therapy (peginterferon alfa-2b and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG000","title":"Placebo+Antiviral Therapy: DB Phase"},{"description":"Participants completing the OL Phase continued on the same dose of eltrombopag received in the OL Phase (dose that effectively raised platelets to \\>=100 Gi/L) in combination with antiviral therapy (peginterferon alfa-2b and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG001","title":"Eltrombopag+Antiviral Therapy: DB Phase"}],"paramType":"NUMBER","populationDescription":"Safety DB Population. Only those participants contributing data at the indicated time points were analyzed.","reportingStatus":"POSTED","timeFrame":"DB Phase: Antiviral BL (up to Week 10); End of Treatment (up to Week 52); and 24-week FU (up to Week 72)","title":"Number of Participants Assessed as Normal and Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points During the DB Phase","type":"SECONDARY","unitOfMeasure":"participants"}